10. Known symptomatic central nervous system (CNS) metastasis and/or carcinomatous meningitis. Subjects received prior treatment and have stable disease more than 4 weeks from first dose of study medication, with neurological symptoms retuned to NCI CTCAE 4.03 grade 0 or 1, are permitted to enroll.